Literature DB >> 25239057

Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies.

Chong Sun1, René Bernards2.   

Abstract

Mammalian cells have multiple regulatory mechanisms to deal with perturbations in cellular homeostasis, including feedback loops and crosstalk between the major signaling pathways. While these mechanisms are critically required to help cells survive under dynamic physiological circumstances, they also pose an impediment to the effective treatment of cancer. In this review, we describe what has been learned about interactions between receptor tyrosine kinase-dependent signaling pathways, and how this knowledge can be used to design rational and more effective combination therapies for cancer.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25239057     DOI: 10.1016/j.tibs.2014.08.010

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  61 in total

1.  Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.

Authors:  Gao Guo; Ke Gong; Vineshkumar Thidil Puliyappadamba; Nishah Panchani; Edward Pan; Bipasha Mukherjee; Ziba Damanwalla; Sabrina Bharia; Kimmo J Hatanpaa; David E Gerber; Bruce E Mickey; Toral R Patel; Jann N Sarkaria; Dawen Zhao; Sandeep Burma; Amyn A Habib
Journal:  Neuro Oncol       Date:  2019-12-17       Impact factor: 12.300

Review 2.  Opportunities and challenges provided by crosstalk between signalling pathways in cancer.

Authors:  A Prahallad; R Bernards
Journal:  Oncogene       Date:  2015-05-18       Impact factor: 9.867

3.  TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.

Authors:  Lipika Goyal; Lei Shi; Leah Y Liu; Ferran Fece de la Cruz; Jochen K Lennerz; Srivatsan Raghavan; Ignaty Leschiner; Liudmila Elagina; Giulia Siravegna; Raymond W S Ng; Phuong Vu; Krushna C Patra; Supriya K Saha; Raul N Uppot; Ron Arellano; Stephanie Reyes; Takeshi Sagara; Sachie Otsuki; Brandon Nadres; Heather A Shahzade; Ipsita Dey-Guha; Isobel J Fetter; Islam Baiev; Emily E Van Seventer; Janet E Murphy; Cristina R Ferrone; Kenneth K Tanabe; Vikram Deshpande; James J Harding; Rona Yaeger; Robin K Kelley; Alberto Bardelli; A John Iafrate; William C Hahn; Cyril H Benes; David T Ting; Hiroshi Hirai; Gad Getz; Dejan Juric; Andrew X Zhu; Ryan B Corcoran; Nabeel Bardeesy
Journal:  Cancer Discov       Date:  2019-05-20       Impact factor: 39.397

4.  The RTK Interactome: Overview and Perspective on RTK Heterointeractions.

Authors:  Michael D Paul; Kalina Hristova
Journal:  Chem Rev       Date:  2018-12-27       Impact factor: 60.622

5.  Feedback analysis identifies a combination target for overcoming adaptive resistance to targeted cancer therapy.

Authors:  Sang-Min Park; Chae Young Hwang; Jihye Choi; Chang Young Joung; Kwang-Hyun Cho
Journal:  Oncogene       Date:  2020-03-10       Impact factor: 9.867

Review 6.  A price to pay for tumor regression.

Authors:  Rene Bernards
Journal:  Cell Res       Date:  2015-04-21       Impact factor: 25.617

7.  Taking advantage of drug resistance, a new approach in the war on cancer.

Authors:  Liqin Wang; Rene Bernards
Journal:  Front Med       Date:  2018-07-18       Impact factor: 4.592

8.  Enhancing Virtual Screening Performance of Protein Kinases with Molecular Dynamics Simulations.

Authors:  Tavina L Offutt; Robert V Swift; Rommie E Amaro
Journal:  J Chem Inf Model       Date:  2016-10-03       Impact factor: 4.956

9.  Benefits of Multifaceted Chemopreventives in the Suppression of the Oral Squamous Cell Carcinoma (OSCC) Tumorigenic Phenotype.

Authors:  Susan R Mallery; Daren Wang; Brian Santiago; Ping Pei; Steven P Schwendeman; Kari Nieto; Richard Spinney; Meng Tong; George Koutras; Brian Han; Andrew Holpuch; James Lang
Journal:  Cancer Prev Res (Phila)       Date:  2016-10-18

10.  Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors.

Authors:  Yuyu He; Jie Li; Tomoyuki Koga; Jun Ma; Sanjay Dhawan; Yuta Suzuki; Frank Furnari; Varun V Prabhu; Joshua E Allen; Clark C Chen
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.